Infektioner I de placebo- kontrollerede kliniske forsøg rapporteredes infektioner, der som minimum var muligt relateret til behandling hos 23, 2% af de abataceptbehandlede patienter og hos 19, 5% af de placebobehandlede.
Infections In the placebo-controlled clinical trials, infections at least possibly related to treatment were reported in 23.2% of abatacept-treated patients and 19.5% of placebo-treated patients.